Stathmins and Motor Neuron Diseases: Pathophysiology and Therapeutic Targets

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Mar 25

PMID 35327513

Authors

Delia Gagliardi

Elisa Pagliari

Megi Meneri

Valentina Melzi

Federica Rizzo

Giacomo Pietro Comi

Stefania Corti

Michela Taiana

Monica Nizzardo

Affiliations

Soon will be listed here.

Abstract

Motor neuron diseases (MNDs) are a group of fatal, neurodegenerative disorders with different etiology, clinical course and presentation, caused by the loss of upper and lower motor neurons (MNs). MNs are highly specialized cells equipped with long, axonal processes; axonal defects are some of the main players underlying the pathogenesis of these disorders. Microtubules are key components of the neuronal cytoskeleton characterized by dynamic instability, switching between rapid polymerization and shrinkage. Proteins of the stathmin family affect microtubule dynamics regulating the assembly and the dismantling of tubulin. Stathmin-2 (STMN2) is one of the most abundantly expressed genes in MNs. Following axonal injury, STMN2 expression is upregulated, and the protein is transported toward the growth cones of regenerating axons. STMN2 has a critical role in axonal maintenance, and its dysregulation plays an important role in neurodegenerative processes. Stathmin-1 (STMN1) is a ubiquitous protein that is highly expressed during the development of the nervous system, and its phosphorylation controls microtubule dynamics. In the present review, we summarize what is currently known about the involvement of stathmin alterations in MNDs and the potential therapeutic effect of their modulation, with a specific focus on the most common forms of MND, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).

Citing Articles

Novel Tissue-Specific Multifunctionalized Nanotechnological Platform Encapsulating Riluzole Against Motor Neuron Diseases.

Esteruelas G, Ettcheto M, Haro I, Herrando-Grabulosa M, Gaja-Capdevila N, Gomara M Int J Nanomedicine. 2025; 20:2273-2288.

PMID: 40007904 PMC: 11853070. DOI: 10.2147/IJN.S479819.

Nuclear Import Defects Drive Cell Cycle Dysregulation in Neurodegeneration.

Plessis-Belair J, Russo T, Riessland M, Sher R bioRxiv. 2025; .

PMID: 39975276 PMC: 11838365. DOI: 10.1101/2025.01.28.635269.

Stathmin 1 expression in neuroendocrine and proliferating prostate cancer.

Shi Y, Yeh Y, Cheng S, Gu X, Yang S, Li L Discov Oncol. 2025; 16(1):19.

PMID: 39776361 PMC: 11711591. DOI: 10.1007/s12672-025-01754-6.

Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.

Faller K, Chaytow H, Gillingwater T Nat Rev Neurol. 2025; 21(2):86-102.

PMID: 39743546 DOI: 10.1038/s41582-024-01049-4.

Targeting STMN2 for neuroprotection and neuromuscular recovery in Spinal Muscular Atrophy: evidence from in vitro and in vivo SMA models.

Pagliari E, Taiana M, Manzini P, Sali L, Quetti L, Bertolasi L Cell Mol Life Sci. 2024; 82(1):29.

PMID: 39725771 PMC: 11671459. DOI: 10.1007/s00018-024-05550-3.

References

Prudencio M, Humphrey J, Pickles S, Brown A, Hill S, Kachergus J . Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020; 130(11):6080-6092. PMC: 7598060. DOI: 10.1172/JCI139741. View

Murray L, Comley L, Thomson D, Parkinson N, Talbot K, Gillingwater T . Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet. 2007; 17(7):949-62. DOI: 10.1093/hmg/ddm367. View

Corti S, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D . Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med. 2012; 4(165):165ra162. PMC: 4722730. DOI: 10.1126/scitranslmed.3004108. View

Di Paolo G, Lutjens R, Osen-Sand A, Sobel A, Catsicas S, Grenningloh G . Differential distribution of stathmin and SCG10 in developing neurons in culture. J Neurosci Res. 1998; 50(6):1000-9. DOI: 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8. View

Zeugin D, Ionta S . Anatomo-Functional Origins of the Cortical Silent Period: Spotlight on the Basal Ganglia. Brain Sci. 2021; 11(6). PMC: 8227635. DOI: 10.3390/brainsci11060705. View

Wang Q, Zhang Y, Wang M, Song W, Shen Q, McKenzie A . The landscape of multiscale transcriptomic networks and key regulators in Parkinson's disease. Nat Commun. 2019; 10(1):5234. PMC: 6868244. DOI: 10.1038/s41467-019-13144-y. View

Lagier-Tourenne C, Polymenidou M, Cleveland D . TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010; 19(R1):R46-64. PMC: 3167692. DOI: 10.1093/hmg/ddq137. View

Rizzo F, Nizzardo M, Vashisht S, Molteni E, Melzi V, Taiana M . Key role of SMN/SYNCRIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons. Brain. 2019; 142(2):276-294. PMC: 6351774. DOI: 10.1093/brain/awy330. View

Glass J . Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration. J Clin Invest. 2020; 130(11):5677-5680. PMC: 7598070. DOI: 10.1172/JCI142854. View

10.

Kapitein L, Hoogenraad C . Building the Neuronal Microtubule Cytoskeleton. Neuron. 2015; 87(3):492-506. DOI: 10.1016/j.neuron.2015.05.046. View

11.

Comley L, Allodi I, Nichterwitz S, Nizzardo M, Simone C, Corti S . Motor neurons with differential vulnerability to degeneration show distinct protein signatures in health and ALS. Neuroscience. 2015; 291:216-29. DOI: 10.1016/j.neuroscience.2015.02.013. View

12.

Graf E, Heerssen H, Wright C, Davis G, DiAntonio A . Stathmin is required for stability of the Drosophila neuromuscular junction. J Neurosci. 2011; 31(42):15026-34. PMC: 3207242. DOI: 10.1523/JNEUROSCI.2024-11.2011. View

13.

Fischer L, Glass J . Axonal degeneration in motor neuron disease. Neurodegener Dis. 2007; 4(6):431-42. DOI: 10.1159/000107704. View

14.

Melamed Z, Lopez-Erauskin J, Baughn M, Zhang O, Drenner K, Sun Y . Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019; 22(2):180-190. PMC: 6348009. DOI: 10.1038/s41593-018-0293-z. View

15.

Curmi P, Gavet O, Charbaut E, Ozon S, Lachkar-Colmerauer S, Manceau V . Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell Struct Funct. 2004; 24(5):345-57. DOI: 10.1247/csf.24.345. View

16.

Bellouze S, Baillat G, Buttigieg D, De La Grange P, Rabouille C, Haase G . Stathmin 1/2-triggered microtubule loss mediates Golgi fragmentation in mutant SOD1 motor neurons. Mol Neurodegener. 2016; 11(1):43. PMC: 4899909. DOI: 10.1186/s13024-016-0111-6. View

17.

Kline R, Kaifer K, Osman E, Carella F, Tiberi A, Ross J . Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases. PLoS Genet. 2017; 13(3):e1006680. PMC: 5391970. DOI: 10.1371/journal.pgen.1006680. View

18.

Alami N, Smith R, Carrasco M, Williams L, Winborn C, Han S . Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014; 81(3):536-543. PMC: 3939050. DOI: 10.1016/j.neuron.2013.12.018. View

19.

Kubota M, Sakakihara Y, Uchiyama Y, Nara A, Nagata T, Nitta H . New ocular movement detector system as a communication tool in ventilator-assisted Werdnig-Hoffmann disease. Dev Med Child Neurol. 2000; 42(1):61-4. DOI: 10.1017/s0012162200000116. View

20.

Wen H, Ting C, Liu H, Li H, Lin-Chao S . Decreased stathmin expression ameliorates neuromuscular defects but fails to prolong survival in a mouse model of spinal muscular atrophy. Neurobiol Dis. 2012; 52:94-103. DOI: 10.1016/j.nbd.2012.11.015. View